Novartis AG EBITDA 2010-2022 | NVS

Novartis AG annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Novartis AG EBITDA for the quarter ending March 31, 2022 was $2.852B, a 18.1% increase year-over-year.
  • Novartis AG EBITDA for the twelve months ending March 31, 2022 was $15.102B, a 16.47% increase year-over-year.
  • Novartis AG 2021 annual EBITDA was $17.764B, a 9.11% increase from 2020.
  • Novartis AG 2020 annual EBITDA was $16.281B, a 9.46% increase from 2019.
  • Novartis AG 2019 annual EBITDA was $14.874B, a 9.21% increase from 2018.
Novartis AG Annual EBITDA
(Millions of US $)
2021 $17,764
2020 $16,281
2019 $14,874
2018 $13,620
2017 $14,705
2016 $14,311
2015 $14,448
2014 $11,089
2013 $15,445
2012 $11,507
2011 $16,760
2010 $15,103
2009 $9,982
Novartis AG Quarterly EBITDA
(Millions of US $)
2022-03-31 $2,852
2021-12-31 $8,031
2021-09-30 $740
2021-06-30 $3,479
2021-03-31 $2,415
2020-12-31 $7,945
2020-09-30 $254
2020-06-30 $2,352
2020-03-31 $2,744
2019-12-31 $3,771
2019-09-30 $3,731
2019-06-30 $2,663
2019-03-31 $2,242
2018-12-31 $3,053
2018-09-30 $2,239
2018-06-30 $2,484
2018-03-31 $2,447
2017-12-31 $3,538
2017-09-30 $2,357
2017-06-30 $2,280
2017-03-31 $1,922
2016-12-31 $3,155
2016-09-30 $3,777
2016-06-30 $3,559
2016-03-31 $3,820
2015-12-31 $1,677
2015-09-30 $3,589
2015-06-30 $3,790
2015-03-31 $4,067
2014-12-31 $2,351
2014-09-30 $3,906
2014-06-30 $4,359
2014-03-31 $3,933
2013-12-31 $3,707
2013-09-30 $3,655
2013-06-30 $3,993
2013-03-31 $4,090
2012-12-31 $2,715
2012-09-30 $4,180
2012-06-30 $4,302
2012-03-31 $3,880
2011-12-31 $3,063
2011-09-30 $4,379
2011-06-30 $4,705
2011-03-31 $4,613
2010-12-31 $3,381
2010-09-30 $3,824
2010-06-30 $3,626
2010-03-31 $4,272
2009-12-31 $2,637
2009-09-30 $3,248
2009-06-30 $2,914
2009-03-31 $2,895
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $188.691B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $479.231B 18.43
Eli Lilly (LLY) United States $310.959B 36.69
Pfizer (PFE) United States $291.093B 10.15
AbbVie (ABBV) United States $270.615B 11.86
Merck (MRK) United States $238.745B 13.49
GlaxoSmithKline (GSK) United Kingdom $111.076B 12.97
Novo Nordisk (NVO) Denmark $0.000B 33.60